CatalystWireBeta

Eroxon to be available on prescription

In brief · summary, not quotable

No summary for this filing – the full text is below.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, confirms that its lead product, Eroxon, will be available on prescription in England and Wales for the treatment of Erectile Dysfunction ("ED") with effect from 1st March 2024. Eroxon is also available without a doctor's prescription having launched in the UK in March 2023.

James Barder, CEO of Futura, commented:

"This milestone builds on the strong progress the Company has made since the initial launch of Eroxon in the UK and is a further step in improving availability of Eroxon, providing access by prescription for men with ED as well as over the counter."

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note